These data suggest that inhibiting tau hyperphosphorylation could disrupt the inflammatory cascade implicated in DCM, thereby reducing cardiac fibrosis, hypertrophy, and dysfunction. This evidence concerns the gene MAPT and familial dilated cardiomyopathy.